Branded

  • Allergan's elevated intraocular pressure treatment gets nod from FDA

    IRVINE, Calif. Allergan's optimized reformulation of Lumigan has received approval from the Food and Drug Administration, the drug maker said Wednesday.

    Lumigan 0.01% (bimatoprost ophthalmic solution) is a first-line therapy indicated for the reduction of elevated intraocular pressure with open-angle glaucoma or ocular hypertension, Allergan said. Lumigan 0.01% will be available in fourth quarter 2010 as the newest addition to Allergan’s comprehensive glaucoma portfolio.

     

  • IMS Health exec to NACDS conference attendees: Expect opportunities, uncertainties for drug market

    SAN DIEGO The U.S. drug market will present opportunities as well as uncertainties over the next decade, according to remarks made by IMS Health VP industry relations Doug Long at the National Association of Chain Drug Stores’ 2010 Pharmacy and Technology Conference held here on Monday.

     

  • Somaxon, P&G to co-promote Silenor

    SAN DIEGO A drug maker and a consumer packaged goods company will co-promote a newly approved insomnia treatment.

    Somaxon Pharmaceuticals and Procter & Gamble announced their co-promotion agreement for Silenor, in which Somaxon's promotion of the drug will target physicans, while P&G will promote Silenor to targeted pharmacies.

  • King names new chief commercial officer

    BRISTOL, Tenn. Jeffrey Bailey has been appointed as King Pharmaceuticals' chief commercial officer, leading all sales, marketing, managed care, sales operations and business analytics for the drug maker.

    BRISTOL, Tenn. Jeffrey Bailey has been appointed as King Pharmaceuticals' chief commercial officer, leading all sales, marketing, managed care, sales operations and business analytics for the drug maker.

  • FDA approves single-pill combination of Novartis drugs for high blood pressure

    EAST HANOVER, N.J. The Food and Drug Administration has approved a single-pill combination of two drugs made by Novartis for treating high blood pressure, the Swiss drug maker said Friday.

     

    The FDA approved Tekamlo (aliskiren and amlodipine besylate) tablets, which combine Tekturna (aliskiren) with amlodipine, a channel blocker available as a generic. The drug is approved for treating patients who are likely to need multiple drugs to lower their blood pressure or as a replacement for patients who can’t control it using one of the drugs alone.

  • FDA gives Sanofi Pasteur the OK to expand use of Menactra vaccine

    SWIFTWATER, Pa. The Food and Drug Administration has accepted an application from Sanofi Pasteur to expand the use of a vaccine in children.

    Sanofi Pasteur, the vaccines division of French drug maker Sanofi-Aventis, announced Thursday the FDA’s acceptance of its application seeking approval of Menactra (meningococcal [groups A, C, Y and W-135] polysaccharide diphtheria toxoid conjugate vaccine) for active immunizations of infants and toddlers against invasive meningococcal disease.

  • Shire to acquire Movetis

  • Bristol-Myers Squibb announces executive changes
X
This ad will auto-close in 10 seconds